DGAP-News: Stellar Biotechnologies Publishes New Corporate Profile
(firmenpresse) - DGAP-News: Stellar Biotechnologies, Inc. / Key word(s): Miscellaneous
Stellar Biotechnologies Publishes New Corporate Profile
13.03.2012 / 15:00
---------------------------------------------------------------------
Stellar Biotechnologies Publishes New Corporate Profile
PORT HUENEME, CA, USA (March 13, 2012) -- Stellar Biotechnologies, Inc.
('Stellar') (FSE: RBT) (TSX-V: KLH) (U.S. OTC: SBOTF) announced today that
the Company has published an update to its corporate profile brochure.
The new profile offers introductory insight into Stellar Biotechnologies'
business activities, industry-leading KLH operations, and management, as
well as a recap of recent milestones.
The material is now available for download at www.StellarBiotech.com and at
http://bit.ly/xREFRk.
Stellar Biotechnologies, Inc. (FSE: RBT)(TSX-V: KLH) (U.S. OTC: SBOTF)
(www.StellarBiotechnologies.com) is the world leader in sustainable
manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important
immune-stimulating protein used in wide-ranging therapeutic and diagnostic
markets. Potent, yet proven safe in humans, KLH operates as both a vital
component for conjugate vaccines (targeting cancer, autoimmune, and
infectious diseases) as well as an antigen for measuring immune status.
Stellar Biotechnologies was founded to address the growing demand for
renewable, commercial-scale supplies of high-quality, GMP-grade KLH.
Stellar has developed leading practices, facilities and proprietary
capabilities to address this need. To receive regular updates, enter email
at bottom of http://stellarbiotechnologies.com/investors/news_releases/
Contact:
Darrell Brookstein, Executive VP, Corporate Development&Finance
dbrookstein(at)stellarbiotech.com
There can be no assurance that forward-looking statements will prove to be
accurate, as actual results and future events could differ materially from
those anticipated in such statements. Readers should not place undue
reliance on such statements. Except in accordance with applicable
securities laws, the Company expressly disclaims any obligation to update
any forward-looking statements or forward-looking statements that are
incorporated by reference herein. This news release does not constitute an
offer to sell, or a solicitation of an offer to buy any of the Company's
securities set out herein in the United States, or to, or for the benefit
or account of, a U.S. Person or person in the United States. Neither TSX
Venture Exchange nor its Regulation Services Provider accepts
responsibility for the adequacy or accuracy of these releases.
End of Corporate News
---------------------------------------------------------------------
13.03.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
160316 13.03.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
" alt="European Uranium Files Technical Report for Kuriskova Preliminary Feasibility Study
Datum: 13.03.2012 - 15:00 Uhr
Sprache: Deutsch
News-ID 124309
Anzahl Zeichen: 3979
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 169 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Stellar Biotechnologies Publishes New Corporate Profile"
steht unter der journalistisch-redaktionellen Verantwortung von
Stellar Biotechnologies, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
